OSM was shown to drive breast cancer progression and metastasis through direct effects on cancer cells, such as suppression of estrogen receptor (ER) expression (32) and promotion of EMT (26, 33), and indirect effects via TME cells, in particular the reprogramming of tumor-associated macrophages and fibroblasts (34–37). The gene discussed is ESR1; the disease is cancer.